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Abstract. Pelzer N, Hoogeveen ES, Haan J, Bunnik R,
Poot CC, van Zwet EW, Inderson A, Fogteloo AJ,
Reinders MEJ, Middelkoop HAM, Kruit MC, van
den Maagdenberg AMJM, Ferrari MD, Terwindt GM
(Leiden University Medical Centre, Leiden; Alrijne
Hospital, Leiderdorp; Leiden University, Leiden,
The Netherlands). Systemic features of retinal
vasculopathy with cerebral leukoencephalopathy
and systemic manifestations: a monogenic small
vessel disease. J Intern Med 2019; 285: 317–332.
Background. Retinal vasculopathy with cerebral
leukoencephalopathy and systemic manifestations
(RVCL-S) is a small vessel disease caused by
C-terminal truncating TREX1 mutations. The dis-
ease is typically characterized by vascular
retinopathy and focal and global brain dysfunction.
Systemic manifestations have also been reported
but not yet systematically investigated.
Methods. In a cross-sectional study, we compared the
clinical characteristics of 33 TREX1 mutation car-
riers (MC+) from three Dutch RVCL-S families with
those of 37 family members without TREX1 muta-
tion (MC-). All participants were investigated using
personal interviews, questionnaires, physical,
neurological and neuropsychological examina-
tions, blood and urine tests, and brain MRI.
Results. In MC+, vascular retinopathy and Raynaud’s
phenomenon were the earliest symptoms present-
ing from age 20 onwards. Kidney disease became
manifest from around age 35, followed by liver
disease, anaemia, markers of inflammation and, in
some MC+, migraine and subclinical hypothy-
roidism, all from age 40. Cerebral deficits usually
started mildly around age 50, associated with
white matter and intracerebral mass lesions, and
becoming severe around age 60–65.
Conclusions. Retinal vasculopathy with cerebral
leukoencephalopathy and systemic manifestations
is a rare, but likely underdiagnosed, systemic
small vessel disease typically starting with vascu-
lar retinopathy, followed by multiple internal organ
disease, progressive brain dysfunction, and ulti-
mately premature death.
Keywords: kidney disease, liver disease, microan-
giopathy, neurology, Raynaud’s phenomenon, thy-
roid disease.
Introduction
Retinal vasculopathy with cerebral leukoen-
cephalopathy and systemic manifestations
(RVCL-S) is an autosomal dominant neurovascular
syndrome caused by heterozygous C-terminal
frameshift mutations in TREX1 and ultimately
leading to premature death [1, 2]. Before the gene
was identified, the disease has been known as
cerebroretinal vasculopathy (CRV) [3], hereditary
vascular retinopathy (HVR) [4], hereditary endothe-
liopathy, retinopathy, nephropathy and stroke
(HERNS) [5] and hereditary systemic angiopathy
(HSA) [6]. The best-known features of RVCL-S are
progressive blindness due to vascular retinopathy,
neurological manifestations of focal and diffuse
brain dysfunction, and white matter and intrac-
erebral mass lesions on neuroimaging [2]. As
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observed in our (outpatient) clinic, complications of
general debilitation due to vascular dementia and
cerebral deficits, for example aspiration pneumo-
nia, are the main cause of premature death in
RVCL-S. Less well described are systemic manifes-
tations such as liver and kidney disease, anaemia,
hypertension and Raynaud’s phenomenon [2]. In
some cases, kidney failure was severe and con-
tributed to a patient’s premature death. As these
systemic features may precede the characteristic
ophthalmological and neurological features of
RVCL-S, establishing a correct diagnosis can be
challenging [2]. To improve early recognition, diag-
nosis and treatment of RVCL-S and, in particular,
its systemic manifestations, we conducted a cross-
sectional study, aimed at better characterizing the
extracranial manifestations of RVCL-S. To this
end, we carefully investigated 33 symptomatic
and asymptomatic RVCL-S TREX1 mutation carri-
ers (MC+) and 37 nonmutation carriers (MC) from
three Dutch RVCL-S families, using a standardized
protocol specifically focussing on systemic signs
and symptoms of the disease.
Materials and methods
Participants and genetic screening
We invited all established MC+ and their 1st and
2nd degree family members aged ≥18 years from
three known (but unrelated) Dutch RVCL-S fami-
lies, regardless of MC status. Consenting family
members with unknown MC status were screened
for TREX1 mutations using genomic DNA extracted
from peripheral leucocytes, PCR and direct Sanger
sequencing as described before [1]. As RVCL-S
cannot yet be treated, participants could opt to
remain unaware of the genetic test results. Family
members without a TREX1 mutation were included
as controls. Matching by age and gender was not
possible due to the limited number of available
family members. The study was approved by the
Medical Ethics Committee of LUMC. All partici-
pants provided written informed consent prior to
inclusion.
Study design
This was a cross-sectional study that, for logistic
reasons, consisted of three standardized visits
(Figure 1). In visit 1, participants were interviewed
to assess disease features and blood was sampled
for DNA isolation. Raynaud’s phenomenon was
diagnosed using the questionnaire by Miller et al.
[7] (cut-off score >4) and the novel international
consensus criteria (except for use of photographs,
which were not available) [8]. A lifetime migraine
diagnosis, including its subtypes, was established
according to the International Classification of
Headache Disorders (ICHD) criteria [9], using a
validated migraine questionnaire [10]. Depression
was established with a score of ≥8 on the Hospital
Anxiety and Depression Scale (HADS-D) [11] and/
or a score of ≥16 on the Centre for Epidemiological
Studies Depression Scale (CES-D) [12], and anxiety
with a HADS-A score of ≥8 [13]. Physical and
cognitive complaints, medical history, medication
use, lifestyle habits and socio-demographic char-
acteristics were assessed during a semistructured
interview.
Most family members with unknown MC status
declined to know their diagnosis. Finding evidence
of vascular retinopathy in a person from a family
with RVCL-S would almost certain confirm the
diagnosis. Not disclosing the results of an ophthal-
mological examination was however not an option
as retinopathy can potentially be treated. We
therefore decided not to screen for retinopathy in
family members with unknown MC status. We did
advise them, though, to consult an ophthalmolo-
gist as soon as they would get visual complaints.
Information on signs of retinopathy in this study
thus came solely from reports of treating ophthal-
mologists of established MC+.
In visit 2, physical examination was performed.
Blood pressure was measured on each arm, in
sitting position, using the same electronic oscillo-
metric device with a cuff around the upper arm.
Hypertension was defined as: (i) use of antihyper-
tensive medication; (ii) systolic blood pressure
>140 mmHg; or (iii) diastolic blood pressure
>90 mmHg [14]. Height and weight were measured
to calculate bodymass index (BMI) and a structured
neurological examination was performed. To assess
general disability, all participants were rated
according to the modified Rankin Scale (mRS) and
the Barthel index of activities of daily living [15, 16].
Blood and urine samples were collected in the
morning, after at least 8 h of fasting (median 12 h,
range 8–17) and were transported immediately for
laboratory assays according to clinical protocols.
Kidney disease was defined as glomerular filtration
rates (eGFR)<60 mL min1per1.73 m2oralbumin-
creatinine ratio or >3 lg lmol1.
In visit 3, all participants first underwent a neu-
ropsychological examination in the afternoon.
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Examinations included the Wechsler memory
scale-fourth edition (WMS-IV) [17] and the Cam-
bridge Cognitive Examination-Revised (CAMCOG-
R). This assesses orientation, language, memory,
attention, praxis, calculation, abstraction and per-
ception [18] and includes the Mini-Mental State
Examination (MMSE) [19]. In the evening, a brain
MRI was performed. Volume of brain white matter
hyperintensities was assessed on FLAIR images
(see for methods legend of Table 5).
Statistical analysis
Variables were reported as medians [interquartile
range (IQR)] or percentages. For continuous
variables without a normal distribution in our
population Mann-Whitney U-tests were applied.
Categorical variables were compared with Pearson
Chi-Square tests, or Fisher’s Exact tests when
appropriate, and by calculating relative risks (RR).
Corrections for multiple testing were not applied,
Fig. 1 Flowchart depicting inclusion of participants from the three Dutch RVCL-S families into the study. Dropouts after visit
1 (interview and questionnaires) and visit 2 (sampling and physical examination) are shown. Six participants (including two
MC+) dropped out after visit 1. Five family members considered multiple visits too much of a burden and one subject was
physically unable to visit the LUMC. For visit 2, the number of physical examinations, urine samples, and vena punctures for
blood sampling are depicted. For visit 3, the number of brain MRIs and neuropsychological examinations (NPE) are shown.
An additional five participants (all MC) could not attend visit 3 because of lack of time. Two MC+ could not complete the
neuropsychological examination because of poor vision and anarthria. Two other MC+ and three MCwithdrew from or had
a relative contra-indication for brain MRI.
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as analyses were meant to be exploratory and
hypothesis-generating. Results with P < 0.05 were
considered statistically significant. All statistics
were performed using SPSS 23.0 (IBM Corp.,
Armonk, NY, USA).
Results
Genetic testing and socio-demographic characteristics of the study
population
In total 103 members of three Dutch RVCL-S
families were invited to participate (Figure 1).
Thirty-three (32%) declined to participate, because:
(i) participation was considered too much of a
burden (n = 21); (ii) they did not want to participate
in any study on RVCL-S (n = 6); (iii) health issues
precluding visiting the hospital (n = 4: one MC+
due to RVCL-S-related poor vision; three
unknown); and (iv) living abroad (n = 2). Of 11
nonparticipants the MC status (6 MC+; 5 MC) and
clinical details were known from previous studies.
Their clinical status did not appear to be different
from participants. The remaining 22 nonpartici-
pants had a 50% (n = 20) or 25% (n = 2) a priori
chance of carrying a TREX1 mutation. Their clin-
ical status was unknown, but most (17/22 = 77%)
were younger than 40 years of age. Overall, non-
participants were younger than participants (me-
dian age 34 vs. 46 years; P = 0.02) and more often
male (25/33 = 76% vs. 30/70 = 43%; P = 0.002).
In total 37 MC and 33 MC+ (23 previously known,
10 newly detected) participated in the study. MC+
and MC did not differ with respect to age, gender,
education level, cigarette pack years, or alcohol
use, but MC+ used less caffeine than MC
(Table 1). With respect to medication use, statins
were only used by MC+ and MC+ used more
antihypertensive drugs. Seven MC+ (median age
57; range 52–65 years) (but none of MC) were
unfit to work, in particular because they were too
slow in performing complex tasks. This impairment
was unrelated to visual impairment. A summary of
all symptoms of RVCL-S is provided in Figure 2.
Association with vascular retinopathy
All known 23 MC+ had signs of vascular retinopa-
thy, of which 15 (65%; median age 57 years) had
undergone (pan)retinal laser photocoagulation. In
six (median age 41 years), retinopathy was mild
not yet requiring treatment. Thirteen experienced
visual field defects (12 after retinal laser photoco-
agulation). In order to remain unaware of their
mutation status, 10 MC+ (median age 24 years),
who were identified during the study, were not
investigated by an ophthalmologist. They did not
have visual complaints.
Association with internal organ disease
Internal organ disease was investigated at three
levels: (i) subjective complaints (Table 2; 33 MC+
and 37 MC); (ii) objective signs at physical exam-
ination (Table 3; 32 MC+ and 32 MC); and (iii)
laboratory tests (Figure 3 and Table 4; 31 MC+ and
33 MC).
Kidney disease was found in 36% of MC+ (Table 2).
Cystitis, pyelonephritis, nephrolithiasis and
haematuria occurred equally frequent in MC+ and
MC. Urine albumin concentrations [median (IQR)
30 (10–96) mg mL1] and microalbumin/crea-
tinine ratios [median (IQR) 6.1 (1.5–13.4)
lg lmol1] were increased in MC+ (Table 4). Albu-
minuria was not explained by concurrent hyper-
tension (Figure S1). Haematuria was not routinely
assessed, but absent in 24-h urine of nine MC+.
Liver disease, usually asymptomatic, was found in
27% of MC+ (Table 2). Five MC+ had a history of
jaundice, four at a young age with jaundice simul-
taneously in relatives in three (i.e. highly sugges-
tive of a shared infectious cause), and one in
association with cholelithiasis. Gamma-glutamyl
transferase (c-GT), alkaline phosphatase (ALP) and
aspartate aminotransferase (ASAT) were increased
in MC+ (Table 4). Most MC+ with elevated liver
enzymes share a same pattern of ALP and cGT 2–3x
ULN (upper limit of normal) and normal to mini-
mally elevated aminotransferase (1-1,5x ULN) and
normal bilirubin levels. None had primary liver
disease. One MC+ had cryptogenic liver cirrhosis
(all other causes of cirrhosis were excluded) and
one had hepatic steatosis. Previous liver ultra-
sound examination did not show abnormalities in
six other MC+ with increased c-GT levels.
A history of anaemia was frequently reported by
MC+ (33%), but also by MC (19%; P = 0.17)
(Table 2). Laboratory results clearly showed lower
haemoglobin and haematocrit levels and slightly
higher mean corpuscular volumes (MCV) in MC+
(Table 4). One MC+ used iron supplements,
another darbepoetin (for severe kidney dysfunc-
tion), and one MC+ just had finished treatment
with iron supplements. Colonoscopy results were
available for four MC+; all had signs of intestinal
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angiodysplasia as a possible source of (gastro)
intestinal bleeding. One patient underwent video
capsule endoscopy, revealing numerous dot-sized
bleeding foci throughout the small intestine. Of the
nine subjects who reported incidental faecal blood
loss, one MC+ was anaemic (haemoglobin 6.2), but
she had noticed (bright red) blood loss only once.
Of the assessed (cardio)vascular complaints only
swollen ankles were more prevalent in MC+
(Table 2). On physical examination, there were no
differences in presence of varicose veins, ankle
oedema or livedo reticularis (Table 3). Prevalence of
hypertension was high in both MC+ (39%) and
MC (35%). Median systolic and diastolic blood
Table 1 Demographics of RVCL-S family members with (MC+) and without (MC) a TREX1 mutation
MC+ (n = 33) MC (n = 37) P-value
Age (years)
Median (IQR) 51.9 (28.6–56.0) 45.2 (38.8–61.9) ns
≥40 years, n (%) 20 (61) 28 (76) ns
Sex
Male, n (%) 14 (42) 16 (43) ns
Males ≥40 years, n (%) 6 (30) 13 (46) ns
Pedigree and TREX1 mutation
A: p.Val235 fs, n (%) 21 (64) 33 (89)
B: p.Val235 fs, n (%) 7 (21) 1 (3)
C: p.Leu287 fs, n (%) 5 (15) 3 (8)
Smoking
Present, n (%) 5 (15) 2 (5) ns
Past, n (%) 11 (33) 12 (32)
Never, n (%) 17 (52) 23 (62)
Median pack years (IQR) 0 (0–2) 0 (0–6) ns
Alcohol use
Median (IQR) (u per wk) 2 (0–9) 3 (0–5) ns
Caffeine use
Median (IQR) (u per day) 5 (3–7) 7 (4–9) P = 0.02
Medication use
Migraine prophylactics, n (%) 1 (3) 0 (0) –
Antihypertensive drugs, n (%) 8 (24) 4 (11) ns
Statins, n (%) 4 (12) 0 (0) –
Thrombocyte aggregation inhibitors, n (%) 5 (15) 3 (8) ns
Anticoagulants, n (%) 0 (0) 1 (3) –
Antidepressants, n (%) 3 (9) 1 (3) ns
Education level
Median (IQR) 4 (3–5) 4 (3–6) ns
1. Primary school, n (%) 0 (0) 1 (3)
2. Secondary 1 (low-level), n (%) 4 (12) 8 (22)
3. Secondary 2 (medium-level), n (%) 5 (15) 2 (5)
4. Secondary 3 (high-level), n (%) 3 (9) 1 (3)
5. Tertiary 1 (low-level), n (%) 14 (42) 10 (27)
6. Tertiary 2 (medium-level), n (%) 5 (15) 15 (41)
7. Tertiary 3 (university), n (%) 2 (6) 0 (0)
IQR, interquartile range; ns, not statistically significant; u, units.
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pressures measured in visit 2 (with standardized
conditions) were virtually the same in MC+ and
MC (Table 3). Only the eldest MC+ reported
coronary artery disease. There were no reports of
(hypertensive) cardiomyopathy in MC+, which was
reported previously in RVCL-S [6, 20, 21].
A novel finding in RVCL-S were increased
thyroid stimulating hormone (TSH) levels with
normal free thyroxine (fT4) levels, indicating
subclinical hypothyroidism (Table 4). One MC+
had been treated for presumed Graves’ disease,
but had normal TSH and fT4 levels while using
levothyroxine.
There were no signs of rheumatic disease (e.g. joint
pains or inflammation), autonomic dysfunction
(e.g. orthostatic hypotension, urine incontinence
or erectile dysfunction), or avascular necrosis of
the femur head [6]. Previous ultrastructural stud-
ies revealed abnormalities in skin samples of
RVCL-S patients [5], but besides livedo reticularis,
varicose veins and ankle oedema (Table 3), which
were not more prevalent in MC+, no skin
abnormalities were found during physical exami-
nation in MC+. With regard to common vascular
risk factors: median BMI (P = 0.31) and cholesterol
levels (P = 0.91) did not differ between MC+ and
MC (Table 3), with only four MC+ taking statins.
Fasting glucose and HbA1c values were normal in
all MC+, ruling out diabetes mellitus. Several
markers of inflammation and coagulation (erythro-
cyte-sedimentation rates (ESR), fibrinogen, D-
dimer concentrations, and prothrombin time (PT))
were increased in MC+, other coagulation markers
were not abnormal in MC+.
Correlating internal organ disease with age
By plotting laboratory parameters against age, we
constructed a pseudolongitudinal course of dis-
ease (Figures 2 and 3; Table 4). Kidney disease
(increased urine albumin and microalbumin-crea-
tinine ratios) were abnormal already before age 40,
while all other internal organ disease developed
from age 40 onwards (Figure 2 and 3).
Association with Raynaud’s phenomenon
The prevalence of Raynaud’s phenomenon was
increased among MC+ according to Miller’s criteria
[RR (95% CI) = 1.90 (1.15–3.13)] and recent inter-
national consensus criteria [RR (95% CI) = 2.24
(1.03–4.88)] (Table 2) [7, 8]. Onset was mostly
before age 20 (10/20 = 50% MC+ and 7/
12 = 58% MC according to Miller’s criteria; 7/
14 = 50% MC+ and 5/7 = 71% MC according to
the international consensus criteria). Symptoms
were mostly mild, and there were no ischaemic
injuries.
Neurological and cognitive features
MC+ more often had subjective memory loss and
focal neurological deficits. Notable neurological
deficits were only found in MC+ older than
50 years.
Lifetime prevalence of migraine was similar in MC+
(27%) and MC (38%); P = 0.35; RR (95%
CI) = 0.72 (0.36–1.42). Aura symptoms were
reported by 6/9 (67%) of MC+ and 12/14 (86%) of
MC with migraine. There was a trend for migraine
starting at a later age in MC+ [median (IQR)=40
(15–43) years] vs. MC [17 (8–20) years; P = 0.07],
which reached significance for migraine with aura
[median (IQR) = 40 (30–47)] years in MC+ versus
MC [median (IQR)=20 (19–22) years; P = 0.01].
Fig. 2 Clinical course of RVCL-S. Symptoms of RVCL-S
derived from previous studies [2] and the current cross-
sectional investigation of RVCL-S patients (aged 18–
65 years). Vascular retinopathy and Raynaud’s phe-
nomenon were the earliest symptoms presenting from
age 20 onwards. Kidney disease became manifest from
around age 35, followed by liver disease, anaemia, and, in
some MC+, migraine and subclinical hypothyroidism, all
from age 40. Cerebral and cognitive deficits usually
started mildly around age 50, associated with increasing
volume of white matter hyperintensities and intracerebral
mass lesions, and becoming severe and ultimately lethal
around age 60–65.
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Except for a higher prevalence of depressive symp-
toms in MC+ ≥40 years, neuropsychological tests
did not reveal clear differences between MC+ and
MC (Table 5). We found no major cognitive
impairment in MC+ [median (IQR) CAMCOG-R
score of 93.0 (89.0–96.0)] in MC+ versus 93.5
(9.0–97.8) in MC. Only the eldest MC+ fulfilled
criteria for dementia.
The volume of white matter hyperintensities on
brain MRI was increased in MC+ ≥ 40 years
(Table 5). While several MC+ had suffered from









Risk Ratio (95% CI)
Kidneys and urinary tract symptoms
Kidney disease, n (%) 12 (36) 1 (3) P < 0.001 13.5 (1.8–98.0)
Frequent cystitis, n (%) 4 (12) 6 (16) ns
Pyelonephritis, n (%) 2 (6) 2 (5) ns
Kidney stones, n (%) 3 (9) 4 (11) ns
Haematuria, n (%) 3 (9) 4 (11) ns
Urine urge incontinence, n (%) 5 (16) 4 (11) ns
Urine stress incontinence, n (%) 1 (3) 5 (14) ns
Hepatic and gastrointestinal symptoms
Liver disease, n (%) 9 (27) 2 (5) P = 0.01 5.0 (1.2–21.7)
Diarrhoea, n (%) 6 (18) 2 (5) ns
Constipation, n (%) 12 (35) 15 (41) ns
Faecal blood, n (%) 5 (15) 4 (11) ns
Cholelithiasis, n (%) 3 (9) 2 (5) ns
Jaundice, n (%) 5 (15) 1 (3) ns
Cardiovascular symptoms
Orthostatic hypotension, n (%) 15 (47) 22 (60) ns
Fatigue, n (%) 15 (46) 10 (27) ns
Anaemia, n (%) 11 (33) 7 (19) ns
Chest pains with exercise, n (%) 2 (6) 3 (8) ns
Exercise-induced dyspnoea, n (%) 9 (28) 4 (11) ns
Palpitations, n (%) 16 (49) 13 (35) ns
Swollen ankles, n (%) 16 (49) 4 (11) P < 0.001 4.5 (1.7–12.1)
Varicose veins, n (%) 11 (33) 11 (30) ns
Intermittent claudication, n (%) 3 (9) 1 (3) ns
Nocturia, n (%) 8 (24) 6 (16) ns
Musculoskeletal symptoms
Joint pains, n (%) 8 (24) 12 (32) ns
Joint inflammation, n (%) 0 (0) 3 (8) ns
Raynaud’s phenomenon a, n (%) 14 (42) 7 (19) P = 0.03 2.2 (1.0–4.9)
Migraineb, n (%) 9 (27) 14 (38) ns
ns, not statistically significant.
aAccording to the international consensus criteria from 2014 [8]. bAccording to the International Classification of
Headache Disorders (ICHD), third edition [9].
Systemic features of RVCL-S / N. Pelzer et al.
ª 2018 The Association for the Publication of the Journal of Internal Medicine 323
Journal of Internal Medicine, 2019, 285; 317–332
Table 3 Results of general disability rating scales and physical examinations in RVCL-S family members with (MC+) and
without (MC) a TREX1 mutation
MC+ MC P-value
Modified Rankin Scale (mRS), n (%) (n = 32) (n = 32) P = 0.002
0 11 (34) 27 (82)
1 10 (31) 5 (15)
2 8 (25) 1 (3)
3 0 (0) 0 (0)
4 2 (6) 0 (0)
5 1 (3) 0 (0)
Barthel index, n (%)
20 24 (75) 30 (91) ns
19 5 (16) 3 (9)
4 1 (3)a 0 (0)
3 1 (3)a 0 (0)
2 1 (3) 0 (0)
Body mass index, measured (n = 29) (n = 33)
Median (IQR) (kg m2) 22.8 (21.5–26.3) 24.9 (21.4–26.9) ns
Hypertension (n = 29) (n = 33)
Present, n (%) 13 (39) 13 (35) ns
Antihypertensive drugs, n (%) 8 (24) 4 (11)
Median systolic (IQR)/diastolic (IQR) blood
pressure (mmHg), visit 1
132 (120–154)/85 (74–98) 128 (121–146)/84 (80–94)
Median systolic (IQR)/diastolic (IQR) blood
pressure (mmHg), visit 2
129 (111–144)/84 (72–94) 128 (117–139)/86 (81–95)
Varicose veins (n = 29) (n = 33)
Present, n (%) 23 (72) 23 (70) ns
Mild, n 14 18 ns
Moderate, n 5 0
Severe (corona phlebectatica), n 4 5
Ankle oedema (n = 29) (n = 33)
Present, n (%) 6 (19) 3 (9) ns
Livedo reticularis (n = 29) (n = 33) ns
Present, n (%) 7 (22) 8 (24)
IQR, interquartile range; ns, not statistically significant.
aTwo subjects were also diagnosed with Multiple System Atrophy, unrelated to RVCL-S.
Fig. 3 Laboratory parameters in blood. Parameters were investigated to assess kidney function (estimated glomerular
filtration rate (eGFR) and microalbumin-creatinin-ratio), liver function [gamma-glutamyl transpeptidase (c-GT) and alkaline
phosphatase], thyroid function [thyroid stimulating hormone (TSH) and free thyroxine (T4)], blood count (haemoglobin), and
inflammation [erythrocyte-sedimentation rate (ESR) and high sensitivity C-reactive protein (CRP)]. One blood glucose assay
and one homocysteine assay failed, both in MC+. Symbols: Black circles and grey boxes: MC+; white circles and boxes:
MC; box plot whiskers: medians, lower and higher quartiles, lower and higher extreme values; *P < 0.05; **P < 0.001.
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intracerebral mass lesions in the past, new ‘pseu-
dotumours’ were not detected.
Discussion
We conducted an extensive and detailed
cross-sectional study into the clinical course and
ophthalmological, cerebral and notably systemic
manifestations of RVCL-S in 33 MC+ and 37 MC
from three Dutch RVCL-S families. Typically, vas-
cular retinopathy and Raynaud’s phenomenon
presented from age 20 onwards, followed by kidney
disease from age 35, and liver disease, anaemia
likely due to gastrointestinal bleeding, migraine,
and subclinical hypothyroidism, from age 40. The
characteristic clinical and neuroimaging manifes-
tations of global and focal brain dysfunction
started mildly around age 50, to progressively
worsen and becoming fatal over the next 10–
15 years. We suggest to add anaemia, gastroin-
testinal bleeding, and subclinical hypothyroidism
as supportive diagnostic criteria for RVCL-S
(Tables 6 and 7).
The sample size of our study, although consider-
able in view of the low prevalence of the disease, is
probably too small for an accurate detailed assess-
ment of the full clinical spectrum of RVCL-S.
Moreover, the cross-sectional design also pre-
cludes an accurate estimate of the exact disease
course over four decades. On the other hand, the
clinical pattern across families and individual
patients appears rather consistent in the present
and previous studies [2, 4, 5]. We therefore believe
that, despite the above limitations, the clinical
characteristics and tentative disease course we
found in our study do seem to reflect the grand
clinical picture of RVCL-S rather well. The gold
standard, a detailed, prospective follow-up study
over several decades in large numbers of MC+ and
families, seems rather impossible.
Other than microvasculopathy due to RVCL-S, we
did not reveal any other good explanation for
internal organ disease in RVCL-S. For instance,
MC+ with albuminuria did not have high blood
pressure and those with liver disease did not have
high alcohol intake. Gastrointestinal bleeding
might explain anaemia in at least some patients
[2], warranting endoscopic evaluation with gastro-
and colonoscopy and possibly targeted treatment.
Large angiodysplasias might require treatment
with endoscopic argon plasma coagulation. Kidney
disease was mild (eGFR > 40 mL min1 per
1.73 m2) and therefore not considered a likely
explanation for anaemia, except perhaps in one
MC+ who had an eGFR of 21 mL min1 per
1.73 m2 and accordingly was treated with darbe-
poetin.
Seven MC+ in our study proved to have subclinical
hypothyroidism, which is a novel finding in RVCL-
S. We did not find any other good explanation in
these MC+, including use of medication [22].
Screening of thyroid function has not been rou-
tinely done in RVCL-S [23]. We are aware of only
one report of hypothyroidism in RVCL-S, a 44-
Table 6 Current diagnostic criteria for RVCL-S [2]
Major diagnostic criteria
Vascular retinopathy (which in the early phases is
associated with retinal haemorrhages, intraretinal
microvascular abnormalities, and/or cotton wool spots)
Features of focal and/or global brain dysfunction
associated on MRI with (i) punctate T2 hyperintense
white matter lesions with nodular enhancement; and/or
(ii) larger T2 hyperintense white matter mass lesions
with rim-enhancement, mass effect, and surrounding
oedema
Family history of autosomal dominant inheritance with
middle-age onset of disease manifestationsa
Demonstration of a C-terminal frameshift mutation in
TREX1 to genetically confirm the diagnosis
Supportive features
On CT focal white matter calcifications and/or on MRI
nonenhancing punctate T2 hyperintense white matter
lesions at an age that non-specific age-related white
matter hyperintensities are infrequent
Microvascular liver disease (nodular regenerative
hyperplasia)
Microvascular kidney disease (arterio- or
arteriolonephrosclerosis, glomerulosclerosis)
Possibly associated features




Migraine with or without aura
Raynaud’s phenomenon (typically mild)
aDe novo mutations may be possible although none have
been reported to date.
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year-old male, but the association with RVCL-S
was considered fortuitous [24]. Of interest,
hypothyroidism has been reported in 14 patients
with Aicardi–Goutieres syndrome, which can be
caused by homozygous missense mutations in
TREX1 [25], that is different to the heterozygous
C-terminal truncating mutations causing RVCL-S.
Subclinical hypothyroidism is also considered a
marker of endothelial dysfunction in diabetic
retinopathy and chronic kidney disease [26, 27].
Subclinical hypothyroidism is a common disorder,
with an estimated prevalence of 6% in the general
population, which may increase to 17% in the
elderly, most prominently in females [28, 29]. The
prevalence of subclinical hypothyroidism in MC
over age 40 is 8% (2/25), and thus comparable to
the prevalence in the general population, the
prevalence in MC+ over age 40 is markedly
increased with 37% (7/19) compared to the general
population.
We found an increased prevalence of Raynaud’s
phenomenon in RVCL-S (42%), in line with previ-
ous reports [2, 30]. Prevalence figures were higher
(both in MC+ and MC) when using Miller’s criteria
[4, 7] than when using the recent international
consensus criteria [8] and greatly exceeded the
prevalence figures of around 5% usually found in
the general population [31]. As a positive family
history of Raynaud’s phenomenon increases the
odds of developing the condition nearly 17-fold
[31], additional genetic risk factors seem to play an
important role as well.
Lifetime prevalence of migraine was lower (27%)
than previously reported (59%) [2]. This might have
been due to that 13/33 = 39% of the newly iden-
tified MC+ in our study was younger than 40 years,
the usual age at onset of migraine in RVCL-S. Many
of these MC+might thus still develop migraine later
on in life. In the general population, migraine
typically starts before age 25 [32]. Why migraine
begins so much later in RVCL-S is unknown but
one could envisage that migraine in RVCL-S is a
secondary phenomenon due to progressive vascu-
lopathy.
Neurological manifestations were associated with
higher white matter hyperintensity volume on MRI
and often remained mild and unnoticed. Cerebral
mass lesions usually present around age 55 and
were, without exception, associated with major
neurological deficits [2]. Depressive symptoms were
more commonamongMC+. Therewasnoevidenceof
major cognitive impairment in our cohort of rela-
tively young patients, but cognitive decline was
present in previously described large cohorts of
RVCL-S patients [2]. Long-term follow-up data are
warranted to get more insight in the exact age at
onset of the symptomatology of RVCL-S.
How RVCL-S TREX1 mutations lead to multiple
organ disease is unknown. Most organs affected in
Table 7 Proposed new diagnostic criteria for RVCL-S.
Major diagnostic criteria
Vascular retinopathy (which in the early phases is
associated with retinal haemorrhages, intraretinal
microvascular abnormalities, and/or cotton wool spots)
Features of focal and/or global brain dysfunction
associated on MRI with (i) punctate T2 hyperintense
white matter lesions with nodular enhancement; and/or
(ii) larger T2 hyperintense white matter mass lesions
with rim-enhancement, mass effect, and surrounding
oedema
Family history of autosomal dominant inheritance with
middle-age onset of disease manifestationsa
Demonstration of a C-terminal frameshift mutation in
TREX1 to genetically confirm the diagnosis
Supportive features
On CT focal white matter calcifications and/or on MRI
nonenhancing punctate T2 hyperintense white matter
lesions at an age that non-specific age-related white
matter hyperintensities are infrequent
Microvascular liver disease (nodular regenerative
hyperplasia)
Microvascular kidney disease (arterio- or
arteriolonephrosclerosis, glomerulosclerosis)





Raynaud’s phenomenon (typically mild)
Migraine with or without aura (typically relatively late
onset)
Hypertension
aDe novo mutations may be possible although none have
been reported to date.
bMoved from possibly associated to supportive features.
cNew supportive criterion
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RVCL-S heavily rely on an intact endothelial bar-
rier to maintain normal function. We found phar-
macological [33] and biochemical evidence for
endothelial dysfunction in RVCL-S [33, 34].
Patients with RVCL-S had abnormal increased
circulating levels of the markers of endothelial
function angiopoietin-2 and Von Willebrand Factor
antigen and propeptide [32]. Neuropathological
studies revealed fibrinoid vascular necrosis or
thickened hyalinized vessels, and multilaminated
basement membranes on ultrastructural images of
both the brain and internal organs, suggesting
endothelial cell damage [2, 5, 35, 36]. Altogether,
this seems to suggest that RVCL-S is a systemic
endotheliopathy.
The underlying mechanisms for the putative
endothelial dysfunction are also unknown.
Atherosclerosis does not seem to play a major role
as vascular risk factors were no more common
amongMC+ thaninMC.Autoimmunemechanisms
have been implicated. TREX1 is a DNA exonuclease
that may prevent autoimmune activation by self-
DNA [37]. RVCL-S frameshift mutations result in a
truncated C-terminus leaving the enzymatic activity
of the N-terminal truncated TREX1 protein intact.
TREX1 escapes nonsense-mediated decay, usually
seen with truncations, as it is a one-exon gene. Lack
of theC-terminalpart of theTREX1protein results in
dysregulation of oligosaccharyltransferase activity
of the endoplasmic reticulum, which in turn leads to
aberrant glycosylation and production of free gly-
cans thatmaytrigger theautoimmuneresponse [38].
Inflammatorymechanismsmight alsobe involvedas
we found increased levels of inflammatory markers
(i.e. ESR, hsCRP, fibrinogen, D-dimer and homocys-
teine) in older MC+.
In summary, RVCL-S is a rare, fatal, and probably
underdiagnosed systemic small vessel disease,
clinically typically starting around age 20 with
progressive blindness due to vascular retinopathy
and Raynaud’s phenomenon. From age 35–40
onwards, most patients will develop multiple inter-
nal organ disease, justifying regular screening,
followed a decade later by progressive characteris-
tic and ultimately fatal cerebral deficits. World-
wide, only 16 unrelated families with confirmed
RVCL-S have been described, of which three orig-
inate from and live in The Netherlands [2]. As this
is a small country with only 17 million inhabitants,
this striking observation does seem to suggest that
many families and patients with RVCL-S remain,
globally, unidentified.
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